The Texas Sharpshooter in the Three Grand Tours (1933-2013): No Evidence for Superior Time Trial Performances in the “Epo Era”


Studies examining effects of doping in professional road racing building on archival records of the three major European stage races—the Tour de France, Giro d’Italia, and Vuelta a España—concluded that riders’ final performances in the “epo era” (>1990) strongly improved, yet declined since 2004. These observations can be criticized. First, we argue that time trial performances are more valid than final performances to indirectly evaluate doping effects. Second, we will pay attention to an informal logical flaw—the Texas sharpshooter fallacy—which may have biased findings and conclusions presented in the studies. To empirically substantiate our critique, we analyzed mean kilometers per hour (km/h) performances realized by winning riders in all time trials on flat and rolling terrain in the three tours (1933-2013, N = 325). Regression analyses revealed no evidence for nonlinear in- or decreases in riders’ speed beyond the 1990s, but a straightforward linear progress over time of b = 0.16 km/h per year (R2 = 0.50, p ≤ 0.001). Findings corroborate our comments on previous archival studies and qualify opinions about effects of the “epo epidemic” on cyclists’ achievements, since the time trial performances delivered in these years are no exemption to the observed linear progress in speed.

Share and Cite:

Lodewijkx, H. and Verboon, P. (2014) The Texas Sharpshooter in the Three Grand Tours (1933-2013): No Evidence for Superior Time Trial Performances in the “Epo Era”. Open Access Library Journal, 1, 1-12. doi: 10.4236/oalib.1101045.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Vandeweghe, H. (2013) Who Has Faith in Cyclists Anymore? [In Dutch: Wie gelooft de coureurs nog?]. Borgerhoff & Lamberigts, Ghent.
[2] USADA (2012) Statement from USADA CEO Travis T. Tygart Regarding the U.S. Postal Service Pro Cycling Team Doping Conspiracy.
[3] USADA (2012) Reasoned Decision of the United States Anti-Doping Agency on Disqualification and Ineligibility.
[4] El Helou, N., Berthelot, G., Thibaut, V., Tafflet, M., Massif, H., Campion, F., et al. (2010) Tour de France, Giro, Vuelta, and Classic European Races Show a Unique Progression of Road Cycling Speed in the Last 20 Years. Journal of Sports Sciences, 28, 789-796.
[5] Perneger, T.V. (2010) Speed Trends of Major Cycling Races: Does Slower Mean Cleaner? International Journal of Sports Medicine, 31, 261-264.
[6] Catlin, D.H., Hatton, C.K. and Lasne, F. (2006) Abuse of Recombinant Erythropoietins by Athletes. In: Molineux, G., Foote, M.A. and Elliott, S.G., Eds., Erythropoietins and Erythropoiesis, Birkhäuser Verlag, Basel, 205-228.
[7] Verbruggen, H. (2001) The EPO Epidemic in Sport. Bloodline Reviews, 1, 3-4.
[8] WADA (2013) World Anti-Doping Agency Prohibited List.
[9] Lundby, C. and Olsen, N.V. (2011) Effects of Recombinant Human Erythropoietin in Normal Humans. Journal of Physiology, 589, 1265-1271.
[10] Lodewijkx, H.F.M. and Brouwer, B. (2011) Some Empirical Notes on the “Epo Epidemic” in Professional Cycling. Research Quarterly for Exercise and Sport, 82, 593-608.
[11] Lodewijkx, H.F.M. and Brouwer, B. (2012) Tour, Giro Vuelta: Rapid Progress in Cycling Performance Starts in the 1980s. International Journal of Sports Science, 2, 24-31.
[12] Lodewijkx, H.F.M. and Verboon, P. (2013) Lance Armstrong’s Era of Performance—Part I: Are His Time Trial Performances Much Different from Other Winners? Journal of Athletic Enhancement, 2, 1.
[13] Jeukendrup, A.E., Craig, N.P. and Hawley, J.A. (2000) The Bioenergetics of World Class Cycling. Journal of Science and Medicine in Sport, 3, 414-433.
[14] Magnier, D., Picq, P., Debreilly, M., Zingoni, P., Haffreingue, H. and Bey, J.-L. (2014) Cycling Remembered. [In French: Mémoire du cyclisme].
[15] Cleveland, W.S. and Devlin, S.J. (1988) Locally-Weighted Regression: An Approach to Regression Analysis by Local Fitting. Journal of the American Statistical Association, 83, 596-610.
[16] Tabachnick, B.G. and Fidell, L.S. (2001) Using Multivariate Statistics. 4th Edition, Allyn and Bacon/Pearson Education Company, Boston.
[17] Lucia, A., Earnest, C. and Arribas, C. (2003) The Tour de France: A Physiological Review. Scandinavian Journal of Medicine and Science in Sports, 13, 275-283.
[18] Kuipers, H. (2006) Putative Effects of Doping in Cycling. [In Dutch: Vermeende effecten van doping in de wieler- sport]. Nederlands Tijdschrift voor Geneeskunde, 150, 2643-2645.
[19] Lodewijkx, H.F.M., Brouwer, B., Kuipers, H. and Van Hezewijk, R. (2013) Overestimated Effect of Epo Administration on Aerobic Exercise Capacity: A Meta-Analysis. American Journal of Sports Science and Medicine, 1, 17-27.
[20] Heuberger, J.A.A.C., Cohen-Tervaert, J.M., Schepers, F.M.L., Vliegenthart, A.D.B., Rotmans, J.I., Daniels, J.M.A., Burggraaf, J. and Cohen, A.F. (2012) Erythropoietin Doping in Cycling: Lack of Evidence for Efficacy and a Negative Risk-Benefit. British Journal of Clinical Pharmacology, 75, 1406-1421.
[21] Hopkins, W.G., Hawley, J.A. and Burke, L.M. (1999) Design and Analysis of Research on Sport Performance Enhancement. Medicine and Science in Sports and Exercise, 31, 472-485.
[22] Fallon, L. and Bell, A. (2005) Viva la Vuelta! The Story of Spain’s Great Bike Race. Mousehold Press, Norwich.
[23] Ninot, G., Connes, P. and Caillaud, C. (2006) Effects of Recombinant Human Erythropoietin Injections on Physical Self in Endurance Athletes. Journal of Sports Sciences, 24, 383-391.
[24] Lundby, C., Robach, P. and Saltin, B. (2012) The Evolving Science of Detection of “Blood Doping”. British Journal of Pharmacology, 165, 1306-1315.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.